Allogene Therapeutics, Inc. (ALLO) stock
ALLONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 3/30
$0.74−0.06 (-7.79%)
Close on Nov 17, 2026Market cap $257.08MP/E –Yield 0.00%
Allogene Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Allogene Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $122.52M, down 31.9% year over year. For fiscal 2025 it was $150.15M, down 21.9% from the year before. The highest annual figure on record is $256.39M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $150.15M | -21.9% |
| FY2024 | Dec 31, 2024 | $192.30M | -20.8% |
| FY2023 | Dec 31, 2023 | $242.91M | -5.3% |
| FY2022 | Dec 31, 2022 | $256.39M | +16.4% |
| FY2021 | Dec 31, 2021 | $220.18M | +14.1% |
| FY2020 | Dec 31, 2020 | $192.99M | +33.5% |
| FY2019 | Dec 31, 2019 | $144.54M | -4.8% |
| FY2018 | Dec 31, 2018 | $151.86M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $30.72M | -23.5% |
| Q1 FY2026 | Mar 31, 2026 | $32.00M | -36.2% |
| Q4 FY2025 | Dec 31, 2025 | $28.63M | -36.3% |
| Q3 FY2025 | Sep 30, 2025 | $31.16M | -30.3% |
| Q2 FY2025 | Jun 30, 2025 | $40.16M | -20.3% |
| Q1 FY2025 | Mar 31, 2025 | $50.20M | -3.9% |
| Q4 FY2024 | Dec 31, 2024 | $44.97M | -17.7% |
| Q3 FY2024 | Sep 30, 2024 | $44.71M | -2.7% |
| Q2 FY2024 | Jun 30, 2024 | $50.36M | -18.8% |
| Q1 FY2024 | Mar 31, 2024 | $52.26M | -34.9% |
| Q4 FY2023 | Dec 31, 2023 | $54.66M | -27.5% |
| Q3 FY2023 | Sep 30, 2023 | $45.98M | -27.8% |
| Q2 FY2023 | Jun 30, 2023 | $62.04M | +8.5% |
| Q1 FY2023 | Mar 31, 2023 | $80.24M | +33.4% |
| Q4 FY2022 | Dec 31, 2022 | $75.42M | +39.7% |
| Q3 FY2022 | Sep 30, 2022 | $63.64M | +8.4% |
| Q2 FY2022 | Jun 30, 2022 | $57.17M | +9.3% |
| Q1 FY2022 | Mar 31, 2022 | $60.16M | +9.0% |
| Q4 FY2021 | Dec 31, 2021 | $53.98M | +3.4% |
| Q3 FY2021 | Sep 30, 2021 | $58.72M | +14.2% |
| Q2 FY2021 | Jun 30, 2021 | $52.29M | +10.6% |
| Q1 FY2021 | Mar 31, 2021 | $55.18M | +31.3% |
| Q4 FY2020 | Dec 31, 2020 | $52.23M | +5.8% |
| Q3 FY2020 | Sep 30, 2020 | $51.42M | +28.6% |
| Q2 FY2020 | Jun 30, 2020 | $47.30M | +48.9% |
| Q1 FY2020 | Mar 31, 2020 | $42.04M | +79.6% |
| Q4 FY2019 | Dec 31, 2019 | $49.36M | +166.8% |
| Q3 FY2019 | Sep 30, 2019 | $40.00M | +267.9% |
| Q2 FY2019 | Jun 30, 2019 | $31.77M | -74.1% |
| Q1 FY2019 | Mar 31, 2019 | $23.40M | – |
| Q4 FY2018 | Dec 31, 2018 | $18.50M | – |
| Q3 FY2018 | Sep 30, 2018 | $10.87M | – |
| Q2 FY2018 | Jun 30, 2018 | $122.49M | – |
See a number that looks wrong?